Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455981 | 0.83 | TRPM8 (0.47) | PPARATRPM8 | |
| SCHEMBL3519974 | 0.83 | TRPM8 (0.47) | PPARATRPM8 | |
| SCHEMBL3519499 | 0.81 | POLB (0.50) | POLBL3MBTL1LMNATSHRTP53 | |
| Acetic Acid SCHEMBL28604975 | 0.79 | LMNA (0.42) | POLBL3MBTL1LMNAMAPTRAB9A | |
| SCHEMBL5620287 | 0.79 | LMNA (0.37) | POLBL3MBTL1LMNATSHRTP53 | |
| SCHEMBL14592012 | 0.79 | LMNA (0.37) | POLBL3MBTL1LMNATSHRTP53 | |
| SCHEMBL5620282 | 0.79 | LMNA (0.37) | POLBL3MBTL1LMNATSHRTP53 | |
| SCHEMBL23618118 | 0.78 | PPARA (0.47) | POLBL3MBTL1LMNAMAPTPPARA | |
| SCHEMBL10509951 | 0.78 | ATM (0.46) | POLBL3MBTL1LMNATSHRMAPT | |
| SCHEMBL5098770 | 0.78 | PPARA (0.44) | POLBL3MBTL1LMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| CN-109369391-A | A kind of synthetic method of fragrance dichloro methyl esters | 南昌大学 | 2019-02-22 | — | — | CN | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1499306-A4 | BICYCLIC AMIDES | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20050203112-A1 | Bicyclic amides | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0071368-B1 | IMIDAZOLINE DERIVATIVES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1985-04-17 | — | — | EP | disclosed |
| US-4411908-A | ANTIMIGRAINE, ANTIDEPRESSANTS | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1983-10-25 | — | — | US | disclosed |
| EP-0071368-A1 | Imidazoline derivatives | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | POLB 4649/4885L3MBTL1 3841/4885LMNA 3733/4885 |
| US-20050203112-A1 | Bicyclic amides | CNR1, CNR2, FAAH | POLB 1642/4885L3MBTL1 3304/4885LMNA 1637/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | POLB 4649/4885L3MBTL1 3841/4885LMNA 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.